Kinstellar has successfully advised the shareholders of the Czech company Quinta-Analytica, an established provider of R&D and regulatory services for the pharmaceutical, biotechnology, and generic drug industries, on the sale of their 75% share in the company to Genesis Private Equity Fund III (GPEF III). Havel, Holasek & Partners advised GPEF III on the transaction.
The transaction represents the first investment for GPEF III, which has approximately EUR 80 million available for investments in small and medium-sized enterprises in the Czech Republic and Slovakia.
Kinstellar describes Quinta-Analytica as "one of the largest companies in CEE providing commercial services for pharmaceutical companies specializing in analytical services that support the development and manufacture of new medicines,” and says that “its services are utilized in the clinical studies and laboratory analyses required by national authorities for drug approval before a new product launch." In 2015, the company achieved revenues of EUR 256 million.
Kinstellar advised the shareholders on all aspects of the transaction, including preparation and negotiation of the transaction documentation, which consisted of a framework agreement, shareholders agreement, and management and consultancy agreement. The firm’s team was led by Partner Jan Juroska, supported by Associate Michal Kniz and Ivana Frantesova.
Havel, Holasek & Partners did not reply to our inquiries on the matter.
Editor’s Note: After this story was published, Havel, Holasek & Partners announced that its team advising Genesis Private Equity Fund III consisted of Partner Vaclav Audes, Managing Associate Jan Frey, and Associate Veronika Filipova.
- Kinstellar Provides Local CEE Advice to Arkema on Acquisition of Den Braven
- Z/C/H Legal Advises CEM VISION on Acquisition of CEMOD-CZ from 3SI Group
- Kinstellar Advises Baring Private Equity Asia on Acquisition of Stake in Telus International
- Lakatos Koves & Partners Takes Team from Kinstellar and Promotes Solyom to Partner
- Creative Solutions in a Critical Cause: Women in Law Firms